ArticleJournal of cancer research and clinical oncology2006
Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction.
Article in Journal of cancer research and clinical oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.
- A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Pooled it
- The prognostic significance of p53 expression in gastric cancer: a meta-analysis.Journal of cancer research and clinical oncology · 2015Pooled it
- The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus.British journal of cancer · 2007Trial
- p53 overexpression is a prognosticator of poor outcome in esophageal cancer.Oncology letters · 2019Article
- Immunohistochemical assessment of protein phosphorylation state: the dream and the reality.Histochemistry and cell biology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAs inactivation of p53 may be correlated with poor response of tumors to chemo- and/or radiotherapy the presence of p53 mutations in exons 5-8 was determined in adenocarcinomas of the gastroesophageal junction (GEJ). As p53 protein phosphorylation at serine 15 indicates stabilization and protection against mdm-2 the presence of this phosphorylation state was subsequently evaluated.
methodsMutations in exons 5-8 were analyzed by denaturing high pressure liquid chromatography (DHPLC) and subsequent sequence analysis in pretherapeutic biopsies of 38 adenocarcinomas of the GEJ that had undergone multimodal treatment in the course of a prospective multicentric phase III trial. The presence of p53 protein phosphorylation at serine 15 was evaluated by immunohistochemistry.
resultsMutations in the DNA binding region were found in 23 samples and were only weakly associated with worse 2-year survival (P=0.083). Phosphorylation at serine 15 of p53 was detected in 14 samples, being neither associated with p53 mutation nor with patient's survival.
conclusionThis allows the conclusion that the determination of these two parameters does not help to select patients who do profit from multimodal treatment for adenocarcinomas of the GEJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.